Trial Profile
A study investigating the treatment effect of Ruxolitinib in Primary Myelofibrosis or Essential Thrombocythemia patients with high risk mutations
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Sep 2016
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis
- Focus Therapeutic Use
- 16 Sep 2016 New trial record